AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 272 min read$ONC

Riva Alessandro sold $66K of ONC

Riva Alessandro sold 212 shares of BeOne Medicines Ltd. (ONC) at $309.51 on 2026-05-22.

Original reporting
SEC EDGAR · Riva Alessandro
Published May 27, 2026, 9:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

The disclosure provides a sentiment datapoint but does not include any operational, clinical, or corporate catalyst; therefore, fundamental repricing is unlikely solely from this event.

02

Market read

Traders may briefly adjust sentiment around ONC based on insider activity, but without additional news the effect should be limited.

03

What to watch

Check whether other insiders/funds also reduced stakes around the same dates; also monitor subsequent filings for pattern vs one-off behavior.

Relevance 6/10Timing: Immediate (new SEC filing), but event is unlikely to reset fundamentals.

Background

This is an SEC Form 4 insider transaction disclosure (director open-market sale) filed after the trade date.

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

BeOne Medicines director Riva Alessandro filed an open-market sale of 212 ONC shares for about $65.6K, leaving 0 shares.

Expected impact

Likely limited immediate impact; watch for follow-on insider activity or sustained selling.

Evidence & confidence

The filing is a small, one-off open-market transaction with no 10b5-1 plan stated; without additional corroborating news, directional read-through is weak.

Market effects

Sector

Minimal; single insider sale in a biotech does not materially change sector risk without accompanying clinical/regulatory catalysts.

Regional

None indicated; filing is US SEC disclosure for an issuer.

Global

None indicated; no international deal/regulatory action mentioned.

Counterpoint

What could challenge this read

The sale may be routine diversification or liquidity need; absence of a 10b5-1 plan does not automatically imply negative expectations.

Key entities

  • issuer
    BeOne Medicines Ltd.

    Subject of the Form 4 insider sale; director sold 212 shares at ~$309.51/share, ending with 0 shares.

  • insider
    Riva Alessandro

    Director who executed the open-market sale disclosed on SEC Form 4.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ONC insider trading history →

Related articles

SEP 1
$ONCHighAI 9/10

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

BeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.

yahoo.com2 min
SEP 1
$ALCMedAI 8/10

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

tradingview.com3 min
SEP 1
$ALCLow

Trump Expands Drug Pricing Agreements With 9 Drugmakers— RFK Jr. Says President Called ‘Every Hour’ to En

President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.

benzinga.com2 min
AUG 31
$ONCHighAI 8/10

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines reported positive Phase 3 trial results for ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), in HER2+ gastroesophageal cancer. The study met its primary endpoint, showing statistically significant overall survival benefits. The FDA recently approved these regimens for first-line treatment. BeOne has rights to ZIIHERA in Asia, Australia, and New Zealand.

leaderpost.com2 min